[{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Duke University School","pharmaFlowCategory":"D","therapeuticArea":"Pharmacology\/Toxicology","country":"ISRAEL","productType":"Other Small Molecule","year":"2024","type":"Collaboration","leadProduct":"Opaganib","moa":"SPHK2","graph1":"Pharmacology\/Toxicology","graph2":"Preclinical","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"RedHill Biopharma \/ Duke University School","highestDevelopmentStatusID":"4","companyTruncated":"RedHill Biopharma \/ Duke University School"},{"orgOrder":0,"company":"The Wistar Institute","sponsor":"Jubilant Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Pharmacology\/Toxicology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Pharmacology\/Toxicology","graph2":"Preclinical","graph3":"The Wistar Institute","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"The Wistar Institute \/ Jubilant Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"The Wistar Institute \/ Jubilant Therapeutics"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Pharmacology\/Toxicology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Ruxolitinib Phosphate","moa":"JAK1\/JAK2","graph1":"Pharmacology\/Toxicology","graph2":"Preclinical","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Incyte Corporation \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"4","companyTruncated":"Incyte Corporation \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"NanoSurface Biomedical","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Pharmacology\/Toxicology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Funding","leadProduct":"Human Ipsc-Derived Cardiac Tissues","moa":"Undisclosed","graph1":"Pharmacology\/Toxicology","graph2":"Preclinical","graph3":"NanoSurface Biomedical","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NanoSurface Biomedical \/ National Institutes of Health","highestDevelopmentStatusID":"4","companyTruncated":"NanoSurface Biomedical \/ National Institutes of Health"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          AAN
                          Not Confirmed
                          AAN
                          Not Confirmed

                          Details : The collaboration is designed to test ABC294640 (opaganib), a first-in-class, orally administered SPHK2 selective inhibitor, as a potential medical countermeasure to treat phosgene inhalation injury.

                          Product Name : Yeliva

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          October 22, 2024

                          Lead Product(s) : Opaganib

                          Therapeutic Area : Pharmacology/Toxicology

                          Highest Development Status : Preclinical

                          Sponsor : Duke University School

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          02

                          AAN
                          Not Confirmed
                          AAN
                          Not Confirmed

                          Details : Mycapssa® (octreotide capsules) is approved in the US for long-term maintenance therapy in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide. Mycapssa® is the first and only oral somatostatin analog approve...

                          Product Name : Mycapssa

                          Product Type : Peptide

                          Upfront Cash : Inapplicable

                          July 14, 2022

                          Lead Product(s) : Octreotide Acetate

                          Therapeutic Area : Pharmacology/Toxicology

                          Highest Development Status : Preclinical

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          AAN
                          Not Confirmed
                          AAN
                          Not Confirmed

                          Details : Collaboration aims to evaluate the ability of Peptidyl Arginine Deiminase 4 (PAD4) inhibitors provided by Jubilant Therapeutics to block neutrophil extracellular trap (NET) formation in the context of COVID-19 related cytokine storms.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Undisclosed

                          January 15, 2021

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Pharmacology/Toxicology

                          Highest Development Status : Preclinical

                          Sponsor : Jubilant Therapeutics

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          04

                          AAN
                          Not Confirmed
                          AAN
                          Not Confirmed

                          Details : The SBIR funding will be used to develop NanoSurface’s innovative platform for modeling and assessing human cardiac function on-a-chip.

                          Product Name : Undisclosed

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          March 03, 2020

                          Lead Product(s) : Human Ipsc-Derived Cardiac Tissues

                          Therapeutic Area : Pharmacology/Toxicology

                          Highest Development Status : Preclinical

                          Sponsor : National Institutes of Health

                          Deal Size : $4.6 million

                          Deal Type : Funding

                          blank

                          05

                          AAN
                          Not Confirmed
                          AAN
                          Not Confirmed

                          Details : Novartis plans to initiate a Phase III clinical trial in collaboration with Incyte to evaluate the use of Jakavi for treatment of severe immune overreaction called cytokine storm in COVID-19.

                          Product Name : Jakavi

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          February 04, 2020

                          Lead Product(s) : Ruxolitinib Phosphate

                          Therapeutic Area : Pharmacology/Toxicology

                          Highest Development Status : Preclinical

                          Sponsor : Novartis Pharmaceuticals Corporation

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank